<DOC>
	<DOCNO>NCT00309972</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin vinorelbine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . It yet know whether give combination chemotherapy follow radiation therapy effective give combination chemotherapy together radiation therapy follow chemotherapy treat non-small cell lung cancer . PURPOSE : This randomized phase III trial study combination chemotherapy follow radiation therapy see well work compare combination chemotherapy combine radiation therapy follow chemotherapy treating patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Cisplatin , Vinorelbine , Radiation Therapy Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient stage III non-small cell cancer treat chemotherapy comprise cisplatin vinorelbine ditartrate ( CV ) follow radical radiotherapy versus concurrent CV chemoradiotherapy follow CV chemotherapy . Secondary - Compare progression-free survival patient treat regimen . - Compare local progression-free survival ( local control ) . - Compare hematological , pulmonary , esophageal , neurological toxicity . - Compare response . - Compare quality life . - Compare cost-effectiveness . OUTLINE : This randomize , multicenter study . Patients stratify accord clinically important factor . Patients randomize 1 2 treatment arm . - Arm I ( sequential treatment ) : Patients receive cisplatin IV 2 hour day 1 vinorelbine ditartrate IV 5-10 minute day 1 8 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Beginning week 15 , patient undergo radiotherapy 5 day week 4 week . - Arm II ( concurrent treatment ) : Patients undergo radiotherapy arm I begin week 1 . Patients receive cisplatin IV 2 hour day 1-4 vinorelbine ditartrate IV 5-10 minute day 1 8 . Chemotherapy repeat every 3 week 4 course absence disease progression unacceptable toxicity . Quality life assess baseline , monthly 6 month , follow-up visit . After completion study treatment , patient follow periodically . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 508 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage III nonsmall cell lung cancer ( NSCLC ) Patients stage IIIB disease must pleural effusion cytologically proven malignant Inoperable disease Disease must able encompass within radical radiotherapy treatment volume PATIENT CHARACTERISTICS : ECOG performance status 0 1 Life expectancy &gt; 3 month Patient consider able tolerate platinumbased chemotherapy radical radiotherapy Glomerular filtration rate ≥ 60 mL/min WBC &gt; 3,000/mm³ Absolute neutrophil count &gt; 1,500/mm³ Hemoglobin &gt; 10.0 g/dL Patients hemoglobin 10 12 g/dL randomization require blood transfusion ensure hemoglobin &gt; 12 g/dL start radiotherapy Platelet count &gt; 100,000/mm³ FEV_1 ≥ 1.0 L DLCO ( transfer factor ) ≥ 50 % predict Alkaline phosphatase ≤ 1.5 time upper limit normal ( ULN ) Gammaglutamyltransferase &lt; 1.5 time ULN Transaminases ≤ 1.5 time ULN Bilirubin ≤ 1.5 time ULN No medically unstable condition ( e.g. , unstable diabetes , uncontrolled arterial hypertension , infection , hypercalcemia , ischemic heart disease ) Not pregnant nursing Fertile patient must agree use effective contraception Negative pregnancy test No previous current malignant disease likely interfere protocol treatment comparison PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>